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Ten antiangiogenic drugs targeting VEGF or its receptors are approved for cancer treatment. However, these
agents, intended to block tumors’ blood supply, may cause hypoxia, which may fuel tumor progression and
treatment resistance. Emerging clinical data suggest that patients whose tumor perfusion or oxygenation in-
creases in response to these agents may actually survive longer. Hence, strategies aimed at alleviating tumor
hypoxia while improving perfusion may enhance the outcome of radiotherapy, chemotherapy, and immuno-
therapy. Here I summarize lessons learned from preclinical and clinical studies over the past decade and pro-
pose strategies for improving antiangiogenic therapy outcomes for malignant and nonmalignant diseases.Tumors acquire blood supply via multiple mechanisms: angio-
genesis (sprouting new vessels from existing vessels), co-
option, intussusception, vasculogenesis, vascular mimicry, and
trans-differentiation of cancer cells into endothelial cells (Carme-
liet and Jain, 2011). More than 40molecules have been identified
to play a critical role in blood vessel recruitment, but most
studies to date have focused on vascular endothelial growth fac-
tor (VEGF) and its receptors. In fact, since 2004, ten drugs that
target VEGF or its receptors have been approved for the treat-
ment of various malignant diseases (Table 1), with many more
in clinical trials. Unfortunately, these agents—used asmonother-
apy or in combination with chemotherapy—have only provided
survival benefits on the order of weeks to months in some tumor
types and have not been efficacious at all in others. Multiple
mechanisms underlie these incremental benefits. In this
Perspective, I will discuss these mechanisms and speculate on
how we can better utilize current antiangiogenic (AA) agents
and develop new ones to improve the benefit to patients with
cancer or other diseases with abnormal vasculature. Instead of
reviewing the entire literature, I will focus on the underlying prin-
ciples, inspired by the works of many in this field, but rely heavily
on insights gained from our own preclinical and clinical studies.
Solid Tumors Develop Resistance to Targeted
Therapies, Including AA Therapies
Millions of advanced cancer patients worldwide have benefitted
from molecularly targeted therapeutics, whether these agents
target oncogenic pathways in cancer cells, angiogenic pathways
in blood vessels, or both. However, some tumors are intrinsically
resistant to these agents, whereas others develop resistance
after an initial response, therefore limiting overall survival bene-
fits to months (Table 1). An important feature that distinguishes
AA drugs from other targeted therapies is that AA agents are
typically given to unselected patients for the approved indica-
tions, whereas cancer cell-targeted therapeutics are given to
only subsets of patients selected on the basis of biomarkers.
Therefore, the informed selection of patients likely to benefit
from AA drugs could significantly improve the benefits derived
from these agents. For example, recent studies show that recur-rent and newly diagnosed glioblastoma (GBM) patients whose
tumor blood perfusion or oxygenation increases after the initia-
tion of AA therapy survive 6–9 months longer than those whose
tumor perfusion does not change or, instead, decreases (Batch-
elor et al., 2013; Emblem et al., 2013; Sorensen et al., 2012).
These emerging data suggest that we should be able to improve
overall survival with a more personalized use of existing AA
agents and by developing novel hypoxia-alleviating agents.
Why Alleviating Hypoxia Is Critical for Improving Cancer
Treatment
The imbalance between pro- and antiangiogenic signaling as
well as physical compression leads to abnormal vessels and
impaired blood perfusion in tumors (Jain 2005, 2013). The
degree of blood flow impairment varies with tumor growth stage
and location and can differ among tumor regions (Movie S1 avail-
able online, embedded in Figure 1) or between a primary tumor
and its metastases. This progressively worsening heterogeneity
in blood perfusion as tumors grow raises an interesting conun-
drum. If a tumor needs blood vessels to grow and tometastasize,
how does it keep growing when growth impairs the very blood
supply that brings the required nutrients and removes waste
products? This apparent paradox can be understood by thinking
about how a reduced blood supply can impart a survival advan-
tage to these renegade cells by creating an abnormal microenvi-
ronment characterized by hypoxia and acidosis (Figure 1).
My hypothesis is that impaired blood supply and the resulting
abnormal tumor microenvironment help cancer cells evade the
immune system, increase their invasive andmetastatic potential,
and apply selective survival pressures to which cancer cell pop-
ulations adapt (Figure 1). Under physiological conditions,
immune cells constantly patrol tissues to identify and destroy
pathogens, foreign antigens, and abnormal cells. However, a
hypoxic and acidic microenvironment reprograms the resident
macrophages (phagocytes)—whose job is to recognize, engulf
and remove dying cells—into a protumorigenic and immunosup-
pressive phenotype (Casazza et al., 2014; Colegio et al., 2014;
Finger and Giaccia, 2010; Hanahan and Coussens, 2012; Keith
et al., 2012; Motz and Coukos, 2013; Noy and Pollard, 2014;Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc. 605
Table 1. Survival Benefits from Anti-VEGF/VEGFR Drugs
Drug Approved Indication
Improvement in
Response Rate (%)
Improvement
in PFS (Months)
Improvement
in OS (Months) Reference
Bevacizumab metastatic colorectal cancer (with
chemotherapy)
10 4.4 4.7 Kindler et al., 2010
0 1.4 1.4 Saltz et al., 2008
14.1 2.6 2.1 Giantonio et al., 2007
metastatic nonsquamous NSCLC
(with chemotherapy)
20 1.7 2 Sandler et al., 2006
16.2 and 13 0.4 and 0.6 NS Reck et al., 2010
metastatic breast cancer (with
chemotherapy)a
15.7 5.9 NS Miller et al., 2007
9 and 18 0.8 and 1.9 NS Miles et al., 2010
11.8 and 13.4 1.2 and 2.9 NS Robert et al., 2011
9.9 2.1 NS Brufsky et al., 2011
metastatic renal cell carcinoma (RCC)
(with IFN-a)
18 4.8 NS Rini et al., 2010
12.4 3.3 NS Escudier et al., 2010
advanced cervical cancer (with
chemotherapy)
12 2.3 3.7 Tewari et al., 2014
Sunitinib metastatic RCC 35 6 4.6 Motzer et al., 2007
GIST 6.8 4.5 NS Demetri et al., 2006
PNET 9.3 4.8 ? Raymond et al., 2011
Sorafenib metastatic RCC 8 2.7 NS Escudier et al., 2007
unresectable HCC 1 NS 2.8 Llovet et al., 2008
unresectable HCC 2 1.4 2.3 Cheng et al., 2009
Pazopanib metastatic RCC 27 5 NA Sternberg et al., 2010
advanced soft tissue sarcoma 6 3 NS van der Graaf et al., 2012
Vandetanib advanced medullary thyroid cancer 43 6.2 NA Wells et al., 2012
Axitinib advanced RCC 10 2 NA Motzer et al., 2013
Regorafenib chemorefractory metastatic colorectal
cancer
0.6 0.2 1.4 Grothey et al., 2013
Aflibercept chemorefractory metastatic colorectal
cancer
8.7 2.2 1.4 Van Cutsem et al., 2012
Cabozantinib advanced medullary thyroid cancer 25 7.2 NS Elisei et al., 2013
Ramucirumab metastatic gastric and GEJ cancers 0.8 0.8 1.4 Fuchs et al., 2014
metastatic GEJ cancers (with
chemotherapy)
12 1.5 2.3 Wilke et al., 2014
metastatic NSCLC (with chemotherapy) NA NA NA M. Perol, 2014, AACR Annual
Meeting Proceedings, abstract
NS, not significant; NA, not available.
aNo longer approved in the United States.
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Hypoxia and acidosis can also attenuate the killing potential of
immune effector cells within the tumor microenvironment. Spe-
cifically, growth factors and cytokines (e.g., transforming
growth factor b [TGF-b] and VEGF) induced by hypoxia or
acidosis suppress the activity of T lymphocytes and inhibit the
ability of dendritic cells to process tumor antigens and present
them to lymphocytes (Barsoum et al., 2014; Calcinotto et al.,
2012; Gabrilovich et al., 2012; Palazo´n et al., 2012). In addition,
hypoxia can directly upregulate, via HIF1a activation, the expres-
sion of the immune checkpoint protein PD-L1 bymyeloid-derived
suppressor cells, dendritic cells, and cancer cells to aid immune
suppression and evasion (Noman et al., 2014).606 Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc.In addition to protection from the immune system, hypoxia
may select for more malignant cells because cells that respond
to physiological cues normally undergo apoptosis under hypoxic
conditions (Wilson and Hay, 2011). Hypoxia can increase the
invasive potential of cancer cells by inducing the production of
promigratory proteins (e.g., SDF1a and HGF) and proinvasive
extracellular matrix molecules (Finger and Giaccia, 2010;
Semenza, 2014). Hypoxia also provides a niche for so-called
cancer stem cells and facilitates inflammation while also confer-
ring resistance to radiation and many widely used therapeutic
agents (Wilson and Hay, 2011). Collectively, these observations
may explain why intratumoral hypoxia correlates with a poor
prognosis in many human cancers (Wilson and Hay, 2011).
Figure 1. Hypoxia and Acidosis Resulting from Impaired Perfusion Fuel Tumor Progression and Treatment Resistance
Shown are adverse consequences of hypoxia and acidosis and some of the molecular players contributing to these: induction of the cancer ‘‘stem cell’’
phenotype (e.g., Akt/b-catenin and OCT4) (Lee and Simon, 2012); resistance to radiotherapy, chemotherapy, and immunotherapy (e.g., fewer oxygen radicals
and cell cycle arrest) (Huang et al., 2013; Neri and Supuran, 2011; Wilson and Hay, 2011); tumor growth and genomic instability and expression of growth factors
(e.g., IGF1 and TGF-a), oncogenes, and tumor suppressor genes (Bindra et al., 2007; Bristow and Hill, 2008; Wilson and Hay, 2011); EMT, invasion, and
metastasis (e.g., CXCR4, Snail, Lox, and cMET) (Finger and Giaccia, 2010; Semenza, 2014); inflammation, immunosuppression, and fibrosis (e.g., IL-6, TGF-b,
SDF1a, tumor-associated macrophage [TAM] polarization, Tregs, and myeloid-derived suppressor cells [MDSCs]) (Casazza et al., 2014; Chen et al., 2014;
Colegio et al., 2014; Motz and Coukos, 2013; Palazo´n et al., 2012; Semenza, 2014); abnormal angiogenesis (e.g., HIFs/VEGF, and Ang2) (Carmeliet and Jain,
2011); resistance to apoptosis/autophagy (e.g., BNIP3) (Semenza, 2014); and switch to anaerobic metabolism (e.g., Glut1, LDHA, and PGK1) (Semenza, 2014;
Vander Heiden et al., 2009). Many of these consequences are dependent on HIF1a, whereas others are not. Therefore, improving tumor perfusion may alleviate
these adverse consequences. The inset shows heterogeneous perfusion in a tumor, leading to hypoxic and acidic regions (reproduced from Vakoc et al., 2009).
See also Movie S1 of heterogeneous perfusion in real time.
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compression of lymphatic vessels also fuels tumor progression
and resistance to treatment but via distinct mechanisms (Jain,
2013). Tumor vessel leakiness worsens interstitial hypertension,
causes edema, and leads to sluggish blood flow because of
clogging of red blood cells concentrated by the leakage of
plasma (Jain, 1988; Netti et al., 1996; Sevick and Jain, 1989).
Tumor vessel leakiness and compression thereby collaborate
in creating a vicious cycle responsible for both acute and chronic
hypoxia as well as acidosis. Therefore, normalizing the tumor
microenvironment by repairing the function of tumor vessels
may be a promising strategy to slow tumor progression and
enhance cancer treatment.
Antiangiogenic Agents Can Normalize the Tumor
Vasculature and Alleviate Hypoxia
The role of blood vessels in tumor progression has been investi-
gated for more than a century (for a review, see Carmeliet and
Jain, 2000). However, the development of AA agents was cata-
pulted by the groundbreaking hypothesis—put forward in 1971by the late Dr. Judah Folkman—that starving tumors by blocking
angiogenesis would slow tumor progression and improve patient
survival (Folkman, 1971). The cloning of VEGF byNapoleone Fer-
rara and his team was a turning point for the field (Ferrara, 2002).
Initially discovered as vascular permeability factor by Harold
Dvorak and colleagues (Dvorak, 2002), VEGF turned out to be
a key survival factor for endothelial cells. This discovery
propelled the development of both small (e.g., tyrosine kinase in-
hibitors [TKIs] and peptides] and large molecular weight (e.g.,
antibodies and receptor bodies) inhibitors of VEGF or its down-
stream signaling (Ferrara, 2002). As anticipated, these inhibitors
alone decreased both blood vessel density and growth of
tumors.
In contrast to most preclinical studies, monotherapy with bev-
acizumab, an anti-VEGF monoclonal antibody, failed to show an
overall survival benefit in patients (Jain, 2005). In multiple ran-
domized phase III trials, bevacizumab conferred a survival
benefit only when given in combination with chemotherapy
(Table 1). These clinical findings seemed paradoxical. Why do
drugs designed to destroy tumor blood vessels benefit patientsCancer Cell 26, November 10, 2014 ª2014 Elsevier Inc. 607
Figure 2. Effect of Vascular Normalization on Tumor Perfusion/Oxygenation
(A) In normal tissue, the blood vessels have normal structure and function because of balance of the signals downstream of the proangiogenic molecules (e.g.,
VEGF and Ang2) and antiangiogenic molecules (e.g., sVEGFR1, thrombospondins, and semaphorins). In contrast, tumor vessels are structurally and functionally
abnormal because of an imbalance between pro- and antiangiogenic signals. This creates an abnormal microenvironment in tumors, characterized by hypoxia,
acidosis, and elevated fluid pressure, that fuels tumor progression and treatment resistance via multiple mechanisms as shown in Figure 1. Inhibiting proan-
giogenic signaling or enhancing antiangiogenic signaling can prune some abnormal vessels and remodel the rest, resulting in a normalized vasculature.
Depending upon the extent of normalization versus pruning, tumor perfusion/oxygenation may increase, remain unchanged, or decrease. Some tumors might be
intrinsically resistant to a given AA agent, and others may switch to nonsprouting mechanisms of vessels recruitment (e.g., vessel co-option) that are refractory to
the given AA agent and continue to make abnormal vessels again. Adapted and updated from Jain (2001) and Sorensen et al. (2012). See also Movie S2 of vessel
co-option.
(B) Thewindow of increased perfusion from vascular normalization depends on the dose and potency of antiangiogenic therapy. High dosesmay cause excessive
pruning of tumor vessels, resulting in a shorter window, and may starve a tumor of oxygen and other nutrients. High doses may also increase toxicity, including
some fatal. Adapted and updated from Jain (2013).
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very blood vessels to reach their target?
I tried to resolve this paradox by proposing that judicious use
of AA agents could transiently ‘‘normalize’’ the abnormal tumor
vasculature, resulting in improved blood perfusion (Figure 2A).
The latter would decrease hypoxia (known to confer resistance
to radio-, chemo-, and immune therapies) and increase drug
accessibility. Therefore, therapies given during the window of
normalization might achieve greater efficacy (Jain, 2001). The
normalized vessels would also resist shedding of cancer cells
from the primary tumor, potentially decreasing metastases
(Jain, 2005). This hypothesis, although controversial, offered a
potential explanation for why bevacizumab can improve the
outcome of chemotherapy and, more importantly, offered guide-
lines to improve such combination therapies (Jain et al., 2006).
Other hypotheses, although not mutually exclusive, also offered
potential reasons for combining AA agents with chemotherapies
(Carmeliet and Jain, 2011). For example, some antiangiogenic
agents may directly kill cancer cells and sensitize endothelial
cells to cytotoxic drugs. Additionally, anticancer agents may
also directly kill endothelial cells. Finally, killing of tumor and
other stromal cells by cytotoxic and/or antiangiogenic agents
may transiently decompress blood vessels, resulting in improved
perfusion. Alternatively, decreased perfusion caused by pruning
excess vessels could block the clearance of anticancer drugs
accumulated in a tumor. This strategy would be especially608 Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc.effective for drugs that are more toxic under hypoxic and/or
acidic conditions.
A variety of preclinical studies using direct and indirect AA
agents supported the normalization hypothesis (Izumi et al.,
2002; Jain et al., 1998; Tong et al., 2004; Winkler et al., 2004;
Yuan et al., 1996). These studies also revealed that blockade
of VEGF signaling or upregulation of thrombospondin transiently
pruned the immature and leaky vessels of tumors in mice and
actively remodeled the remaining vasculature so that it more
closely resembled the normal vasculature. The morphological
changes were accompanied by functional improvements:
decreased IFP, decreased tumor hypoxia, and improved pene-
tration of macromolecules from these vessels in these tumors.
Radiation therapy had a better outcome when given during the
normalization window comparedwith prior to or after the normal-
ization window (Winkler et al., 2004). We also discovered that
Tie-2 activation contributed to the increased pericyte coverage,
and that an increase in matrix metalloproteinase (MMP) activity
repaired the basement membrane (Winkler et al., 2004).
Although the focus of this Perspective is primarily on VEGF in-
hibition because of its clinical relevance, a number of other
molecular targets, present in cancer and a variety of host cells,
that facilitate or hinder vascular normalization have also been
investigated (Goel et al., 2011) (Figure 3 and Table 2). Several
agents that target these pathways are now in clinical trials
(e.g., Ang-2/Tie-2 and FGFR) (Vasudev and Reynolds, 2014).
Figure 3. Pathways that Facilitate or Hinder Vascular Normalization
Although most studies on vascular normalization have focused on VEGF, a number of molecular players can facilitate (green) or hinder normalization (red). Note
that the outcome may be dose- and context-dependent. Table 2 provides further details about each of these molecular players. The tumor cell is depicted near
endothelial cells to save space. Adapted and updated from Goel et al. (2011).
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cancer patients, has been shown to induce vascular normaliza-
tion by enhancing Notch signaling in endothelial cells, leading
to improved blood perfusion in tumors and reduced metastasis
(Figure 3) (Maes et al., 2014).
Increased Tumor Perfusion/Oxygenation Appears to
Confer Survival Benefits
A phase I/II trial in rectal carcinoma patients revealed that a sin-
gle dose of bevacizumab decreased vessel density, increased
pericyte coverage, and lowered the interstitial fluid pressure in
tumors (Willett et al., 2004). A subsequent trial in recurrent
GBM patients demonstrated that cediranib, an oral pan-VEGFR
TKI, normalized tumor vessels and alleviated edema (Batchelor
et al., 2007). However, the improvement in progression-free sur-
vival (PFS) and overall survival (OS) correlated with the extent of
normalization (Sorensen et al., 2009). Notably, cediranib tran-
siently increased perfusion and oxygenation in a subset of recur-
rent and newly diagnosed GBMpatients, and only these patients
survived longer (Batchelor et al., 2013; Emblem et al., 2013;
Sorensen et al., 2012). Similar findings on increased oxygenation
and pathological response have been reportedwith bevacizumabin patients with locally advanced breast cancer (J. Garcia-Foncil-
las et al., 2012, J. Clin. Oncol., abstract).
These clinical trials suggest that, for a given dose/schedule of
AA agents, some patients whose tumor perfusion/oxygenation
increases benefit, whereas others do not. However, these find-
ings need to be tested in prospective randomized trials. If vali-
dated, increased perfusion/oxygenation early in treatment could
serve as a potential predictive biomarker for AA therapy. The
next important challenge is to determine why, for the same
dose of AA agents, tumor perfusion goes up only in some
patients and not in others.
Benefits of Vascular Normalization Are AA Dose- and
Drug Size-Dependent
As originally hypothesized, the extent of vascular normalization
in a primary or metastatic lesion is likely dependent on the
dose of anti-VEGF/R drugs relative to the level of VEGF in that
lesion (Figure 2B). Very high doses of anti-VEGF/R agents could
cause a rapid reduction in blood perfusion for a tumor with a
certain level of VEGF by excessive vessel pruning and might
not improve the outcome of concurrent therapies. High doses
may increase hypoxia, resulting in increased metastasis andCancer Cell 26, November 10, 2014 ª2014 Elsevier Inc. 609
Table 2. Molecules Linked with Tumor Angiogenesis and Vascular Normalization
Molecule Complete Name Cell Type Localization References
Ang1 angiopoietin 1 pericyte soluble factor Huang et al., 2010; Winkler et al., 2004
Ang2 angiopoietin 2 endothelial soluble factor Huang et al., 2010; Nasarre et al., 2009
BRAF proto-oncogene B-Raf tumor intracellular Bottos et al., 2012; Goel et al., 2012
c-Met hepatocyte growth factor receptor
(HGFR)
tumor transmembrane Goel et al., 2012; You et al., 2011
Connexin-43 connexin 43 endothelial transmembrane Zhang et al., 2014
Dll4 delta-like ligand 4 endothelial transmembrane Hellstro¨m et al., 2007
EGFR epidermal growth factor receptor tumor transmembrane Izumi et al., 2002
eNOS endothelial NOS endothelial intracellular Fukumura et al., 2006; Goel et al., 2013
FAK focal adhesion kinase tumor, endothelial intracellular Skuli et al., 2009
FN fibronectin extracellular matrix
(ECM)
extracellular Chiang et al., 2009
Frizzled frizzled endothelial transmembrane Elisei et al., 2013
HIF hypoxia-inducible factor tumor, endothelial intracellular Semenza, 2014
i/nNOS inducible/neuronal nitric oxide
synthases
tumor cells intracellular Fukumura et al., 2006; Kashiwagi et al., 2008
Lactate lactate endothelial intracellular Goveia et al., 2014; Ve´gran et al., 2011
LAMA4 laminin a4 ECM extracellular Seano et al., 2014a; Zhou et al., 2004
LDH lactate dehydrogenase endothelial intracellular Goveia et al., 2014; van Beijnum et al., 2006
MCP-1 monocarboxylate transporter 1 endothelial transmembrane Goveia et al., 2014
MMP14 matrix metalloproteinase 14 tumor, endothelial transmembrane E.I. Ager, S.V. Kozin, N.D. Kirkpatrick, G. Seano,
D.P. Kodack, V. Askoxylakis, Y. Huang, S. Goel,
M. Snuderl, A. Mizikansky, D.M. Finkelstein,
D.T. Dransfeld, L. Devy, Y. Boucher, D. Fukumura,
and R.K.J., unpublished data; Seano et al., 2014b
MMP2 matrix metalloproteinase 2 tumor, endothelial soluble factor Fang et al., 2000; Winkler et al., 2004
MMP9 matrix metalloproteinase 9 tumor, endothelial soluble factor Jodele et al., 2005; Winkler et al., 2004
Netrin-1 netrin 1 ECM extracellular Castets and Mehlen, 2010
Notch1 notch homolog 1 endothelial transmembrane Hellstro¨m et al., 2007; Phng and Gerhardt, 2009
NRP-1 neuropilin 1 endothelial transmembrane Maes et al., 2014; Maione et al., 2009
PDGF-B,C platelet-derived growth factor B, C endothelial soluble factor Abramsson et al., 2003; di Tomaso et al., 2009
PDGFR PDGF receptor pericyte transmembrane Abramsson et al., 2003; di Tomaso et al., 2009
PFKFB3 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 3
endothelial intracellular De Bock et al., 2013; Goveia et al., 2014
PHD2 HIF-prolyl hydroxylase 2 tumor, endothelial intracellular Mazzone et al., 2009
PI3K phosphatidylinositol bisphosphate
3-kinase
tumor intracellular Karar and Maity, 2011
PlGF placental growth factor endothelial soluble factor Fischer et al., 2008
Ras Ras family tumor intracellular Karar and Maity, 2011; Zhang et al., 2001
Rgs5 regulator of G-protein signaling 5 pericyte intracellular Hamzah et al., 2008
RhoB ras homolog gene family, member B tumor cells intracellular Skuli et al., 2009
SEMA3A semaphorin 3A endothelial transmembrane Maione et al., 2009
TGFR TGF receptors endothelial transmembrane Liu et al., 2012
TGFb transforming growth factor b tumor soluble factor Liu et al., 2012
Tie2 TIE 2 endothelial transmembrane Huang et al., 2010; Winkler et al., 2004
TNFR TNF receptors endothelial transmembrane Johansson et al., 2012
TNFa tumor necrosis factor a tumor soluble factor Calcinotto et al., 2012; Johansson et al., 2012
TSP-1 thrombospondin 1 ECM extracellular Lawler and Lawler, 2012
VE-cadherin vascular endothelial cadherin endothelial transmembrane Maes et al., 2014; Orsenigo et al., 2012
VEGF-A vascular endothelial growth factor A tumor, endothelial soluble factor Batchelor et al., 2007; Ferrara, 2002; Winkler
et al., 2004
(Continued on next page)
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Table 2. Continued
Molecule Complete Name Cell Type Localization References
VEGFR2 VEGF receptor endothelial transmembrane Ferrara, 2002; Sitohy et al., 2012; Winkler et al.,
2004
VE-PTP VE-protein tyrosine phosphatase endothelial transmembrane Goel et al., 2013
WNT WNT family endothelial soluble factor Reis et al., 2012; Zhang et al., 2001
a5b1 integrin a5b1 integrin endothelial transmembrane Magnussen et al., 2005
a6b1 integrin a6b1 integrin endothelial transmembrane Seano et al., 2014a, 2014b
avb3 integrin avb3 integrin tumor, endothelial transmembrane Seano et al., 2014b; Skuli et al., 2009
avb5 integrin avb5 integrin tumor, endothelial transmembrane Skuli et al., 2009
b-catenin b-catenin endothelial intracellular Reis et al., 2012
For additional references, see Goel et al. (2011). The effects of many of these molecules are context- and dose-dependent.
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lower doses might improve perfusion and outcome. Indeed, low
doses of an anti-VEGFR2 antibody (10 or 20 mg/kg) increased
perfusion compared with a high dose (40 mg/kg) or control
immunoglobulin G (IgG) in a breast cancer model (Huang et al.,
2012).
There are no clinical data directly comparing the dose effect of
anti-VEGF agents on perfusion or oxygen levels. However, a
study showed decreased perfusion and uptake of docetaxel in
the non-small-cell lung cancer in patients after administration
of 15 mg/kg bevacizumab (Van der Veldt et al., 2012). Unfortu-
nately, unlike the GBM trials (Batchelor et al., 2013; Sorensen
et al., 2012), this study did not look at the time course of perfu-
sion or drug uptake, nor did it examine whether these two
parameters correlated with the treatment outcome. So, although
this clinical study does show a decrease in perfusion with a
15 mg/kg dose, it does not reveal whether this reduction in
perfusion translated into a survival benefit for these patients. If
starving tumors were the key mechanism of benefit from bevaci-
zumab, as generally hypothesized, one would expect lower PFS
and OS with a lower dose of bevacizumab, assuming the lower
dose will not saturate the VEGF target. However, there was no
statistically significant difference in PFS or OS in non-small-cell
lung cancer patients treated with 15 or 7.5 mg/kg bevacizumab
with chemotherapy (Reck et al., 2010). Whether lowering the
dose below 7.5 mg would have increased PFS or OS in these
patients is not known. These results collectively argue for
tailoring the dose and schedule of anti-VEGF agents for individ-
ual patients using imaging or other biomarkers, including the
levels of VEGF and its receptors in the primary tumor and meta-
static lesions.
The size of concurrently administered drugs is also important
because anti-VEGF therapy is likely to lower the size of pores in
tumor vessels, therefore lowering the extravasation of drugs
(Hobbs et al., 1998). For example, in a number of preclinical
studies and a clinical study, bevacizumab has been shown to
decrease the uptake of antibodies (e.g., trastuzumab and cetux-
imab) (S. Oosting et al., 2012, J. Clin. Oncol., abstract; Arjaans
et al., 2013; Heskamp et al., 2013; Pastuskovas et al., 2012). In
contrast, in a breast cancer model in mice, low-dose anti-
VEGFR2 antibody (5 or 10 mg/kg compared with the standard
dose of 40 mg/kg) improved the delivery of antibody-sized
nanoparticles (12 nm) but not larger nanoparticles (60 or
120 nm), whereas higher doses did not improve the delivery ofeither (Chauhan et al., 2012). Furthermore, combination therapy
with a low dose of anti-VEGFR2 antibody (5mg/kg) improved the
efficacy of 10 nm nab-paclitaxel (Abraxane) but not 100 nm lipo-
somal doxorubicin (Doxil) (Chauhan et al., 2012). Therefore, the
dose of anti-VEGF agents may need to be tailored for the size
of concurrently administered therapeutics and may compromise
the delivery of therapeutics beyond a certain size for a given
tumor. All this, of course, makes the optimal use of AA agents
more complex.
Although a number of preclinical studies have shown
increased perfusion and drug uptake in tumors with a variety of
AA agents (Goel et al., 2011; Maes et al., 2014), there are no clin-
ical studies to date that have measured both the time course of
perfusion and drug uptake along with the survival benefit. The
closest to drug uptake kinetics has been the measurement of
oxygen supply, which, similar to perfusion kinetics, seems to
support the benefit of vascular normalization (Emblem et al.,
2013; Batchelor et al., 2013). It is possible that the benefit of
vascular normalization may come primarily from improved tumor
oxygenation resulting from improved perfusion, rather than
improved drug uptake, for various reasons discussed earlier
(Figure 1).
Overcoming Resistance to AA Therapy Using
Biomarkers
Because tumors use multiple pathways for recruiting vessels, it
is not surprising that blocking VEGF/R alone has inconsistent
or incomplete effects on tumor vasculature. For example, non-
sprouting mechanisms may be predominant in some treat-
ment-naive tumors (e.g., vessel co-option in the metastatic
legions in the lungs, liver, and lymph nodes) or may become
operative as a means of escape from anti-VEGF therapy in other
tumors (e.g., vessel co-option in GBM) (Movie S2). Some of
these mechanisms may be triggered by molecules produced in
response to increased hypoxia (e.g., HGF, SDF1a, and Ang2)
resulting from excessive pruning by longer treatment duration
and/or higher doses of anti-VEGF agents. Some treatment-naive
tumors may have a majority of blood vessels invested in peri-
cytes and, therefore, remain resistant to VEGF blockade (Sitohy
et al., 2012). Other tumors may have excessive amounts of
endogenous anti-VEGF molecules (e.g., sVEGFR1, NRP1, and
thrombospondin) and may therefore not respond to exogenous
VEGF blockade (Duda et al., 2010). Finally, cellular mechanisms
involving various immune cell populations (Gr-1+ myeloid cellsCancer Cell 26, November 10, 2014 ª2014 Elsevier Inc. 611
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resistance to AA therapy (Chung et al., 2013; Hanahan andCous-
sens, 2012; Noy and Pollard, 2014; O¨hlund et al., 2014).
To gain insights into the molecular players involved in intrinsic
and evasive resistance to anti-VEGF agents, we and other inves-
tigators have measured a panel of molecules in the tumor-tissue
or circulation of patients undergoing AA therapies. Correlating
the levels of these tissue/circulating biomarker candidates with
treatment outcome has revealed candidate pathways potentially
involved in treatment resistance to anti-VEGF therapies.
For example, elevated levels of sVEGFR1 prior to treatment
were associatedwith a poor outcome frombevacizumab in rectal
carcinoma, hepatocellular carcinoma (HCC), and metastatic
colorectal carcinoma patients (Duda et al., 2010; Meyerhardt
et al., 2012; Raut et al., 2012; Willett et al., 2009; Zhu et al.,
2013). Additionally, high levels of sVEGFR1were also associated
with fewer side effects in rectal and liver cancer patients (Duda
et al., 2010; Zhu et al., 2013). Finally, a retrospective analysis
has shown that a genetic polymorphism in theVEGFR1 gene cor-
relates with increased VEGFR1 expression and a poor outcome
of bevacizumab treatment in metastatic renal cell carcinoma
and pancreatic ductal adenocarcinoma patients (Lambrechts
et al., 2012). Similarly, elevated levels of NRP1 were associated
with a poor outcome in some trials (Lambrechts et al., 2013). It
is possible that VEGFR1 and NRP1 function as endogenous
VEGF traps. Therefore, adding an external anti-VEGF agent
may not have significant biologic effects in patients with high
sVEGFR1/NRP1 levels (Jain, 2013). Additionally, increased
VEGFR1 levels may induce increased proangiogenic signaling
by PlGF when VEGF is blocked (Lambrechts et al., 2012). These
hypothesis-generating findings need to be tested prospectively,
and, if validated, alternate pathways need to be targeted in pa-
tients with elevated sVEGFR1/NRP1 levels. Along these lines,
the baseline level of the short form of VEGF (VEGF-A121) is a pre-
dictive biomarker in some studies but not in others (Lambrechts
et al., 2013) and is being prospectively examined in a breast can-
cer trial (ClinicalTrials.gov identifier NCT01663727).
As an example of evasive resistance, circulating levels of the
chemokine SDF1a rise in patients who evade various anti-
VEGF therapies, including rectal carcinoma with bevacizumab,
GBMwith cediranib, HCCwith sunitinib, and soft tissue sarcoma
with sorafenib (Duda et al., 2011). The SDF1a/CXCR4 pathway is
involved in vessel co-option, vasculogenesis, fibrosis, lympho-
cyte trafficking, and cancer cell invasion, depending on the tumor
and treatment. For example, in HCC, this pathway appears to in-
crease fibrosis, whereas, in GBM, it appears to facilitate the inva-
sion of cancer cells and co-option of host vessels by invading
cancer cells (Chen et al., 2014; N.D. Kirkpatrick and R.K. Jain,
2010, American Association for Cancer Research Proceedings,
abstract; Movie S2). The latter finding has led to a clinical trial
with AMD3100 (an anti-CXCR4 drug) plus bevacizumab in recur-
rent GBM patients (ClinicalTrials.gov identifier NCT01339039).
Other evasive pathways include Ang2/Tie2/VE-PTP and HGF/
cMET, which play important roles in vascular structure and func-
tion (e.g., pericyte coverage and permeability) and cell invasion
(Figure 3) (Sennino et al., 2012; Vasudev and Reynolds, 2014;
M. Hidalgo et al., 2014, ASCO Annual Meeting Proceedings, ab-
stract). In addition, cellular mechanisms of resistance involve the
participation of local or bone marrow-derived populations of612 Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc.immune cells (e.g., Gr-1+ myeloid cells and Th17 cells) or peri-
cyte coverage, which promote resistance through direct support
of paracrine interactions with the endothelial cells (Carmeliet and
Jain, 2011; Chung et al., 2013). A number of agents that target
these evasive pathways are now in clinical trials (Vasudev and
Reynolds, 2014).
Targeting VEGF versus VEGFR2 May Have a Different
Outcome
Because VEGFR2 is thought to be the main receptor conveying
the proangiogenic signals downstream of VEGF, it is generally
assumed that targeting VEGFR2 would have similar biological
effects as targeting the ligand. However, this is not the case in
somemalignancies. For example, although bevacizumab mono-
therapy has not improved overall survival in any phase III trial, the
anti-VEGFR2 antibody ramucirumab led to an OS advantage of
1.4 months in advanced gastric or gastresophageal junction
(GEJ) adenocarcinomas (Table 1). Interestingly, when added to
paclitaxel, ramucirumab also increased OS by 2.3 months in pa-
tients with GEJ tumors (Table 1). When combined with chemo-
therapy, both bevacizumab and ramucirumab failed to improve
OS in metastatic breast cancer, but both improved survival in
non-small-cell lung cancer (NSCLC) (Table 1). It is tempting to
assume that blood vessels of GEJ tumors are highly or even
exclusively dependent on VEGFR2 signaling for their survival,
and, hence, ramucirumab’s benefits result from starving these
tumors, which is in support of the original antiangiogenesis hy-
pothesis. However, the starvation hypothesis does not explain
the failure of bevacizumab in the same tumor type.
Blood Vessels Are Not the Only Target of Antiangiogenic
Agents
As pointed out above, the targets of AA agents include not only
blood vessels but also subsets of cancer and stromal cells. For
example, VEGF can serve as a survival factor, promote epithe-
lial-mesenchymal transition (EMT), and support the stem cell
phenotype in cancer cells. VEGF can also block the maturation
of dendritic cells (Goel and Mercurio, 2013). Similarly, PlGF—a
member of the VEGF family—functions as a survival factor for
medulloblastoma cells and facilitates their spread through the
cerebrospinal fluid via neuropilin 1 (NRP1) signaling (Snuderl
et al., 2013). Other angiogenic molecules, including angiocrines
such as platelet-derived growth factor (PDGF), angiopoietins,
SDF1a, and TGF-b, also support the survival, proliferation, and
migration of various types of cancer and stromal cells (Butler
et al., 2010). Similarly, sunitinib targets both VEGFR and c-KIT,
which is commonly mutated in gastrointestinal stromal tumor
(GIST) cells. Therefore, AA agents, and especially multireceptor
TKIs, may affect tumor growth andmetastasis bymultiple mech-
anisms, making the task of deciphering their primary mechanism
of action or identifying predictive biomarkers more complex.
Future studies that incorporate tissue, circulating, and imaging
biomarkers are needed to resolve these outstanding issues.
Agents Targeting Oncogenic Pathways Can Also
Normalize Tumor Vessels
Although agents targeting endothelial or perivascular cells can
directly induce vascular normalization, inhibition of oncogenic
signaling can have the same effect indirectly. In 1998, we
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dependent carcinoma are primarily vascular (preceding tumor
cell death) because of an indirect mechanism of hormone deple-
tion that suppresses tumor cell production of angiogenic factors
(Jain et al., 1998). We subsequently showed that inhibition of hu-
man epidermal growth factor receptor 2 (HER2) signaling in
breast cancer cells using trastuzumab normalizes breast tumor
vessels by modulating the expression of at least four pro- and
antiangiogenic molecules (Izumi et al., 2002). Moreover, several
other reports describe similar effects from inhibiting oncogenic
pathways (e.g., Ras, phosphatidylinositol bisphosphate 3-ki-
nase [PI3K], AKT, epidermal growth factor receptor [EGFR],
and BRAF), which can lower the expression of VEGF and other
proangiogenic molecules (Goel et al., 2012). Hence, such agents
have the potential to improve tumor oxygenation via dual mech-
anisms: improved perfusion through normalization of vessels
and reduced oxygen consumption by dying cancer cells.
Combining Antiangiogenic Agents with Drugs that
Target Oncogenic Pathways
Combining AA agents with agents targeting oncogenic path-
ways, similar to chemotherapeutic agents, has led to some
unexpected results. For example, despite promising preclinical
results from combining VEGF- and EGFR-targeted agents in
colorectal and NSCLC models, all phase III trials combining
these targeted agents failed (Tol et al., 2009). Similarly, phase
III trials combining VEGF and HER2-targted therapies in
HER2+ breast cancer patients also failed (Gianni et al., 2013).
A potential mechanism for these failures, as suggested above,
is that the dose of bevacizumab used may have decreased the
size of pores in the tumor vessel walls and compromised the de-
livery of antibodies (Chauhan et al., 2012). This hypothesis is
consistent with elevated baseline plasma VEGF concentrations
being associated with a greater bevacizumab benefit. It is also
consistent with the recent randomized phase II trial showing
the benefit of combining bevacizumab with a smaller drug, erlo-
tinib, in EGFR-mutant NSCLC patients (Seto et al., 2014).
Unfortunately, in all of these trials, patients with CNSmetasta-
ses were excluded. We discovered that treatment of HER2+
breast tumors in the mouse brain with trastuzumab leads to
increased VEGF production by host cells in the brain (Izumi
et al., 2002). To this end, we combined HER2-targeted drugs
(trastuzumab and lapatinib) with an anti-VEGFR2 antibody and
demonstrated a significant improvement in survival of mice
bearing HER2+ tumors in the brain (Kodack et al., 2012). More-
over, a phase II clinical trial with dual HER2 blockade and beva-
cizumab showed encouraging results in heavily pretreated
HER2+ breast cancer patients with brain metastases (Falchook
et al., 2013). Whether this will translate into increased OS in brain
metastasis patients in a phase III trial remains to be seen.
Combining Antiangiogenic Agents with Vessel-
Decompressing Agents
Diminished blood perfusion and hypoxia in tumors results not
only from the abnormal structure and leakiness of tumor vessels,
but also from the compression of vessels by extravascular com-
ponents in tumors (Chauhan et al., 2013, 2014; Jain, 1988, 2014;
Padera et al., 2004; Stylianopoulos et al., 2012). This is evident in
highly desmoplastic tumors where a large fraction of vessels iscompressed and may contribute to the failure of AA therapies
in these patients (e.g., pancreatic ductal adenocarcinomas, a
subset of breast cancers) (Kindler et al., 2010). Moreover,
some tumors begin to produce more extracellular matrix in
response to VEGF blockade, partly from increased hypoxia,
and become treatment-resistant (Aguilera et al., 2014; Chen
et al., 2014). Therefore, strategies that can alleviate compressive
forces exerted by stromal cells and/or the extracellular matrix in
desmoplastic tumors should decompress tumor vessels and
sensitize these tumors to AA agents. In fact, when Shh blockade
improves perfusion in desmoplastic pancreatic ductal adenocar-
cinomas in mice, these tumors become responsive to an anti-
VEGFR2 antibody (Rhim et al., 2014). Additionally, agents that
can normalize both desmoplastic stroma and abnormal blood
vessels may be effective in these treatment-resistant tumors
(Stylianopoulos and Jain, 2013).
Our laboratory has recently discovered that widely prescribed
antihypertensive drugs—angiotensin receptor blockers and ACE
inhibitors, collectively known as renin-angiotensin system (RAS)
inhibitors—can inhibit cancer-associated fibroblasts’ activity to
decrease the production of collagen I and hyaluronan, reduce
compressive forces in tumors, open up blood vessels in desmo-
plastic breast and pancreatic ductal adenocarcinomas in mice,
and improve the delivery and efficacy of chemotherapeutics
(Chauhan et al., 2013). We are currently developing agents that
can realize this goal without significantly lowering blood pres-
sure. Other antifibrotic agents (e.g., pirfenidone, PEGPH20)
may also benefit the treatment of desmoplastic tumors (Chauhan
et al., 2014; Kozono et al., 2013). However, given the heteroge-
neity of stromal cells and the pro- and antitumor signals they
impart, the choice of molecular target for depleting stroma is crit-
ical. For example, a recent study utilized the genetic ablation of
SMA+ cells to deplete stroma in desmoplastic pancreatic tumors
(O¨zdemir et al., 2014). Because pericytes, required to maintain
vessel integrity, are also SMA+, this strategy destroyed many
blood vessels and increased hypoxia. As expected (Figure 1),
this genetic SMA+ cell depletion approach induced EMT, stem
cell phenotype, invasion, metastasis, inflammation, and immu-
nosuppression by increasing hypoxia in these tumors.
Although there are no prospective clinical data on the combi-
nation of RAS inhibitors with standard therapies, retrospective
studies show that metastatic renal cell carcinoma patients sur-
vive 7 months longer when they receive RAS inhibitors in combi-
nation with sunitinib compared with sunitinib alone (30 versus
23 months) (Keizman et al., 2011). Similarly, another retrospec-
tive study of 2,277 advanced lung cancer patients showed better
overall survival when RAS inhibitors were given concurrently
with chemotherapy alone or chemotherapy and bevacizumab
(A.R. Menter et al., 2014, ASCO Annual Meeting Proceedings,
abstract). Because a significant fraction of cancer patients
develop hypertension during the course of AA therapy, and
because RAS inhibitors are fairly safe and relatively inexpensive,
it would be worthwhile to test this hypothesis prospectively. Be-
sides RAS inhibitors, it would also be of interest to test whether
alleviation of desmoplasia by nintedanib, an AA agent that tar-
gets VEGFR, FGFR, and PDGF receptor (PDGFR) and proven
to be effective in idiopathic pulmonary fibrosis, contributed to
the survival benefit in combination with docetaxel in lung adeno-
carcinoma patients (Reck et al., 2014; Richeldi et al., 2014).Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc. 613
Figure 4. Vascular Normalization Can
Reprogram the Tumor Microenvironment
from Immunosuppressive to
Immunosupportive
The abnormal tumor vasculature can impede
T effector cell infiltration into tumors and create
a hypoxic and acidic tumor microenvironment
that upregulates PD-L1 on MDSCs, dendritic
cells, and cancer cells; increases the accumula-
tion of regulatory T cells (Tregs); impairs T effector
cells; and polarizes TAMs to the immune
inhibitory M2-like phenotype to suppress T
effector cell function. Hypoxia can also upre-
gulate multiple immune-suppressive growth fac-
tors and cytokines (e.g., VEGF and TGF-b).
Vascular normalization with an appropriate
dose and schedule of antiangiogenic treat-
ment can normalize the tumor vasculature and
generate a more homogeneous distribution of
perfused tumor vessels, facilitating the infiltration
of T effector cells while reducing MDSC and Treg accumulation. In addition, alleviation of hypoxia and acidity by improved vascular perfusion
polarizes TAMs to an immunostimulatory M1-like phenotype. Adapted and updated from Huang et al. (2013).
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Recently approved immune checkpoint inhibitors have led to un-
precedented improvements in overall survival in melanoma
patients (Wolchok et al., 2013). However, a subset of patients
even in this highly responsive disease does not benefit. Addition-
ally, the first Food and Drug Administration (FDA)-approved ther-
apeutic vaccine, sipuleucel-T, where autologous dendritic cells
are exposed to a fusion protein consisting of GM-CSF and pros-
tatic acidic phosphatase and then infused back into the body,
demonstrated a modest survival benefit of a fewmonths. Finally,
various vaccine and adoptive T cell therapies, including with
chimeric antibody receptors (CAR), have shown promise in
various malignancies (Ogino et al., 2011). We hypothesize that
normalizing the tumor microenvironment will improve the
outcome of all of these different immunotherapies and poten-
tially allow lowering the dose of immunotherapeutic agents,
which, in turn, may decrease their toxicity (Huang et al., 2013).
As stated earlier, the abnormal microenvironment of tumors
helps tumors evade the immune response through multiple
mechanisms, including impairment of lymphocyte infiltration,
upregulation of immune checkpoint protein expression via hyp-
oxia, recruitment of Tregs, and establishment of an immunosup-
pressive tumormicroenvironment that impairs the function of the
resident and transiting immune effector cells (Figure 4) (Huang
et al., 2013; Motz et al., 2014). Our laboratory has demonstrated
that normalizing doses of anti-VEGFR2 antibody (DC101) can
alleviate hypoxia, improve the delivery of immune effector cells
into the tumor, convert the immunosuppressive microenviron-
ment of tumors into an immunostimulatory one, and improve
survival from a vaccine therapy (Huang et al., 2012). There are
also a number of preclinical studies that show the benefit of
combining AA agents with various immunotherapies (Table 3).
Whether vascular normalization played any role in these results
remains unknown. Regardless, clinical trials combining immune
checkpoint blockers and other immunotherapies with AA agents
have begun (Table 3).
Targeting Endothelial Cell Metabolism Can Inhibit
Tumor Angiogenesis
Until recently, only molecular signals such as VEGF and others
have been demonstrated to regulate angiogenesis. However,614 Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc.endothelial cells require energy and new biomass to proliferate
and migrate during new vessel formation. Carmeliet and col-
leagues have recently discovered increased glycolysis via the
glycolytic activator PFKFB3 in leading endothelial cells, known
as the tip cells, during sprouting angiogenesis (De Bock et al.,
2013; Schoors et al., 2014). PFKFB3-driven glycolysis is also
required for proliferating stalk endothelial cells that elongate
the vascular sprout. These studies show that endothelial cell
metabolism plays a pivotal role in vessel sprouting. Furthermore,
pharmacological blockade of PFKFB3 inhibited pathological
angiogenesis with modest side effects. These studies provide
a paradigm shift in previous antiglycolytic strategies that aimed
to block glycolysis maximally and permanently but at the cost
of causing severe toxicity. Therefore, targeting tumor endothelial
cell metabolism opens up new possibilities for AA therapy.
Whether targeting PFKFB3 also blocks nonsprouting modes of
vessel recruitment is not known.
Antiangiogenic Agents Cause Toxicities
Similar to most cancer therapeutics, AA agents may lead to car-
diovascular and noncardiovascular adverse effects, some of
which may be fatal in 1.5%–2.5% of patients. These toxicities
are dependent not only on the class of AA agents (targeting
VEGF versus VEGFR versus VEGFR-TKI), but also on the
specific AA agent. Cardiovascular toxicities include hyperten-
sion, thromboembolic disease, left ventricular dysfunction,
myocardial ischemia, and prolongation of the QTc interval. Non-
cardiovascular toxicities include proteinuria, bleeding, delayed
wound healing, gastrointestinal perforation, fatigue, thyroid
dysfunction, stomatitis, myelosuppression, cutaneous effects
(including hand-foot syndrome), and dysphonia. Other rare
and AA agent-specific adverse effects include reversible
posterior leukoencephalopathy, osteonecrosis of the jaw, micro-
angiopathic hemolysis, pancreatic enzyme elevations, and
hypoglycemia. Some of these adverse effects are dose-
dependent and are even reversible, whereas others are not.
Retrospective studies have shown an association between
some of these (e.g., hypertension) and the survival benefit,
but none have been proven prospectively. Some of the
adverse effects appear contradictory, such as hemorrhage
and thrombosis, which makes their management challenging
Table 3. Combination of Immunotherapies with Antiangiogenic Agents
Antiangiogenic Immunotherapy Tumor Models Results
Preclinical Studies
Anti-VEGFR2 monoclonal
antibody (mAb)
whole tumor cell vaccine
(secreting GM-CSF)
breast carcinoma
(Neu-expressing)
[ trafficking of CD8+ T cells
[ regression of tumor in FVB mice (Manning
et al., 2007)
Anti-VEGFR2 mAb whole tumor cell vaccine
(mitomycin-treated)
breast carcinoma [ recruitment of CD4+ and CD8+ T cells
Y MDSCs and Tregs
[ survival (Huang et al., 2012)
Adenoviral delivery of
sVEGFR1/R2
whole tumor cell vaccine
(secreting GM-CSF)
colon carcinoma,
melanoma
[ infiltration of CD4+ and CD8+ T cells
Y MDSCs and Tregs
[ survival (Li et al., 2006)
VEGF peptide mimic HER-2 B cell epitope vaccine breast carcinoma [ High affinity HER-2 native antibodies
[ antitumor and antiangiogenic effects
Y tumor growth (Foy et al., 2012)
SU 6668 whole tumor cell vaccine
(irradiated) and recombinant
B7.2-IgG fusion protein
breast carcinoma [ recruitment of CD8+ T cells, tumor growth delay
(Huang et al., 2002)
Sunitinib Pox virus-based vaccine expressing
carcinoembryonic antigen and
costimulatory molecules
colon carcinoma [ intratumoral T cells
Y MDSCs and Tregs
Y tumor volume and [ survival (Farsaci et al.,
2012)
Sorafenib anti-PD-1 antibody with a
CXCR4 inhibitor (AMD3100)
hepatocellular
carcinoma
[ intratumoral T cells
Y MDSCs and Tregs
Y primary and metastatic tumor volume and
[ apoptosis (T. Reiberger et al, 2014, Hepatology,
abstract)
Anti-mouse VEGF mAb peptide-pulsed dendritic
cells (DCs)
sarcoma [ DC number and function.
[ tumor growth delay (Gabrilovich et al., 1999)
Anti-mouse VEGF mAb- anti-gp100 pmel-1 T cells,
gp100 vaccine, IL-2 after
lymphodepletion
melanoma [ immune cell infiltration
[ tumor growth delay
[ survival (Shrimali et al., 2010)
VEGFR-1 CAR-modified T cells lung carcinoma Y endothelial tube formation in vitro
[ tumor growth delay and Y metastasis (Wang
et al., 2013)
Anti-VEGFR2 anti-PD-1 antibody colon carcinoma [ inhibition of tumor neovascularization
[ T cell infiltration
[ expression of cytokines (Yasuda et al., 2013)
Clinical Studies
NA peptide vaccine (VEGFR1,
VEGFR2, URLC10, TTK,
or CDCA1)
NSCLC [ T cell response
[ Stable disease for 2 months (Suzuki et al., 2013)
NA antiangiogenic peptide
vaccine
different solid
tumors
[ activation of T cells
Antitumor activity being evaluated (Hayashi et al.,
2013)
Sunitinib RCC Y number and function of MDSCs and Tregs
(Ko et al., 2009)
Bevacizumab IFN-a2A metastatic RCC [ progression-free survival (Escudier et al., 2010)
Bevacizumab ipilimumab advanced melanoma [ T cell infiltration (Hodi et al., 2014)
Bevacizumab nivolumab NSCLC ClinicalTrials.gov identifier NCT01454102
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comprehensive recent review on these adverse effects
and their management, please see http://www.uptodate.
com/contents/toxicity-of-molecularly-targeted-antiangiogenic-
agents-cardiovascular-effects and http://www.uptodate.
com/contents/toxicity-of-molecularly-targeted-antiangiogenic-
agents-non-cardiovascular-effects.) It is tempting to postulate
that reducing the dose of AA agents would not only reduce
toxicity but may also increase the extent of normalization and
delay the onset of hypoxia with all its negative consequences.
However, there are no phase III randomized trials to date that
compare the effect of a high versus a low dose of the same AA
agent on efficacy or toxicity.
AnimalModels of Cancer andExperimental DesignNeed
to Be Improved
A major challenge in the AA therapy of cancer has been the
discordance between the preclinical and clinical results. There
are many potential reasons for this, including limitations of avail-
able animal models as well as the experimental design. First, the
preclinical tumor models used generally grow rapidly and are
more sensitive to anti-VEGF agents than their human counter-
parts (with the notable exception of renal cell carcinomas).
Genetically engineered mouse models (GEMMs) are less genet-
ically complex than human tumors and rarely metastasize simi-
larly to the human disease. Patient-derived xenograft models
are improving with the development of mice with a more human-
ized immune system. Second, almost all AA agents have been
approved for metastatic disease, whereas most preclinical
studies examine the effect on primary tumors (corresponding
to the neoadjuvant setting in the clinic). Although better murine
models of advanced disease are now being developed, preclin-
ical studies are rarely carried out in the adjuvant or metastatic
settings (Francia et al., 2011). It is worth noting that the FDA
will provide accelerated approval upon demonstration of a sub-
stantial increase in the pathological complete response rate for
patients with aggressive breast cancers (e.g., triple-negative),
with full approval conditional on the eventual demonstration of
improvements in disease-free and OS rates as well as accept-
able toxicity (Prowell and Pazdur, 2012). Third, although both
bevacizumab and aflibercept have shown improved OS only
when combinedwith chemo- or immune therapies, most preclin-
ical studies tested these agents as monotherapies. Fourth,
although bevacizumab does not recognize mouse VEGF, many
investigators use bevacizumab in their murine studies, therefore
not addressing the contribution of host VEGF in the outcome.
Fifth, in many preclinical studies, the dose of AA agents has
been unusually high, potentially leading to misleading results
(Chung et al., 2012). Sixth, many studies using GEMMs in which
the relevant gene is knocked out in the embryo represent preven-
tion rather than intervention studies. Hence, the findings may not
translate to the treatment setting and can even derail treatment
strategies. Seventh, murine models tend to underestimate
toxicity. We need to take these limitations into account in both
experimental design and data interpretation.
The Normalization Strategy Can Benefit Patients with
Nonmalignant Diseases
Abnormal vessels are a hallmark of not only cancer but also of a
number of nonmalignant diseases that afflict more than half a616 Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc.billion people worldwide. These include wet age-related macular
degeneration (AMD) and diabetic macular edema. Vascular
normalization seems to be a major mechanism of benefit from
the approved anti-VEGF agents (Jain, 2005). Neurofibromatosis
2 (NF2)-associated schwannomas also harbor abnormal vessels
causing edema, whichmay contribute to hearing loss by disrupt-
ing auditory nerve function. Additionally, inflammatorymolecules
produced as a result of hypoxia may also trigger hearing loss
(Roosli et al., 2012). Indeed, low-dose bevacizumab improved
hearing in 60% of NF2 patients treated on a compassionate-
use basis (Plotkin et al., 2009). A follow-up phase II study showed
a durable hearing benefit in approximately 36% of patients
(S. Plotkin, personal communication). Bevacizumab is now
approved for NF2-related schwannomas in the United Kingdom.
Other potential applications of vascular normalization include
controlling plaque rupture, neurovascular complications stem-
ming from radiation therapy, and tuberculosis (Jain et al., 2007;
Solano et al., 2007). Unfortunately, similar to cancer, the nonma-
lignant diseases also become resistant to anti-VEGF therapies.
Fortunately, the benefit may last years in the latter compared
with only a couple of months in the former (Table 1). One cause
of failure may be fibrosis, presumably instigated by hypoxia
resulting from prolonged VEGF blockade. Additionally, some
vessels may be refractory to VEGF blockade because of pericyte
coverage. Phase II data suggest that prevention of fibrosis
and pruning of resistant vessels with a PDGF inhibitor may
prolong the benefit of ranibizumab in patients with wet AMD
and has led to a phase III trial (ClinicalTrials.gov identifier
NCT01940900). A number of trials that target PDGF or Ang2
along with VEGF to prolong the benefit to patients are planned
or ongoing (Ratner, 2014).
Summary and Perspective
In conclusion, AA therapy, despite being given to unselected pa-
tients, has benefitted numerous patients worldwide who had no
other alternative treatment options. Similar to various therapeu-
tic approaches that looked straightforward in the beginning, anti-
angiogenesis has turned out to be more complex and nuanced
than originally envisaged for multiple reasons.
First, a major part of the complexity in AA therapy stems from
multiple mechanisms employed by tumors to recruit blood ves-
sels. These mechanisms seem to vary not only spatially and
temporally within a tumor but also between a primary tumor
and its metastases and among tumor types. Moreover, tumors
may switch from one mechanism to another during growth and
in response to treatment. Although VEGF seems to be a central
player in sprouting angiogenesis, our knowledge of the molecu-
lar players in other mechanisms is still in its infancy. Understand-
ing these mechanisms in more detail will allow the development
of novel agents to target all types of tumor vessels and enhance
the treatment outcomes from these agents via vascular normal-
ization and/or starvation.
Second, the initial focus of antiangiogenic therapy was to
target endothelial cells, pericytes, and/or the basement mem-
brane in which they are invested. Now we know that these cells
interact not only with each other and cancer cells but also with
the extracellular matrix and other stromal cells in the tumor
microenvironment, including resident and transiting immune
cells, cancer stem cells, as well as fibroblasts/myofibroblasts.
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Although our understanding of the biochemical crosstalk be-
tween the stroma and cancer cells has grown exponentially,
our understanding of the physical microenvironment is in its early
stages (Jain et al., 2014). The physical forces exerted by the tu-
mor stroma can directly induce cancer cell invasion (Tse et al.,
2012) and compress blood and lymphatic vessels. As discussed
earlier, the resulting hypoxia, acidosis, and interstitial hyperten-
sion can fuel tumor heterogeneity, progression, and treatment
resistance. Furthermore, forces exerted by plasma and intersti-
tial fluid can also affect vessel formation and function (Song
and Munn, 2011). Therefore, strategies to control these forces
are likely to yield new ways of alleviating hypoxia, slowing tumor
progression and reducing treatment resistance.
Third, not only blood vessels but also other components of the
tumor microenvironment are abnormal, and all of these abnor-
malities in concert seem to fuel tumor progression and treatment
resistance. Therefore, we need to develop therapeutic agents
that normalize the entire tumor microenvironment, including im-
mune and other stromal cells, and not just the tumor blood ves-
sels. Limited preclinical as well as retrospective clinical studies
suggest targeting the rennin-angiotensin system as a promising
approach for normalizing CAFs in desmoplastic tumors, which
account for about 25% of human tumors. Similarly, a number
of agents that aim to normalize the immune microenvironment
have been approved, and others are being tested. In the long
run, a judicious combination of these agents is likely to yield a
significant benefit to patients while reducing their toxicity.
Finally, unlike cancer cell-targeted therapies, many AA
agents are not directly cytotoxic but directly affect vascular
permeability. Thismakes interpreting contrast-enhanced images
complicated. Hence, the search for biomarkers has been chal-
lenging.Most biomarker studies have focused on circulating bio-
markers that are unable separate the response of the host from
that of neoplastic lesions. Tissue biomarkers, based generally
on limited samples of tumors, do not account for the heterogene-
ity inherent in all malignancies. Advanced imaging techniques
can provide both spatial and temporal information but are expen-
sive and use protocols that may not be standardized acrossmul-
tiple institutions. A limited number of correlative trials have used
all three approaches and have provided powerful insights into the
mechanisms of response and resistance. However, these trials
have been small. Hence, these findings need to be validated in
prospective, randomized trials. Importantly, future trials with
novel agents need to integrate all three types of biomarkers.
Addressing these challenges and judiciously using existing
and newly developed AA agents, alone or with other emerging
therapeutic approaches, is likely to increase the survival benefits
in selected patients while sparing other patients from unneces-
sary and expensive treatments.
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